Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide of Different Volumes: Comparing 0.1 ml vs 0.05 ml

Sung Yong Park; Kyung Seek Choi

doi:10.3341/jkos.2008.49.4.589

Journal List > J Korean Ophthalmol Soc > v.49(4) > 1008234

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Choi: Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide of Different Volumes: Comparing 0.1 ml vs 0.05 ml

Original Article

J Korean Ophthalmol Soc 2008;49(4):589-594.

Published online: 7 September 2008

DOI: https://doi.org/10.3341/jkos.2008.49.4.589

Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide of Different Volumes: Comparing 0.1 ml vs 0.05 ml

Sung Yong Park, M.D., Kyung Seek Choi, M.D.

Department of Ophthalmology, Soonchunhyang University, College of Medicine, Seoul, Korea

Address reprint requests to Kyung Seek Choi, M.D. Department of Ophthalmology, College of Medicine, Soonchunhyang University #657-58 Hannam-dong, Yongsan-gu, Seoul 140-743, Korea Tel: 82-2-7099354, Fax: 82-2-798-7797, E-mail: ckseek@naver.com

Received 14 June 2007 Accepted 2 October 2007

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To assess whether a 4 mg/0.05 ml intravitreal triamcinolone acetonide injection can reduce the IOP elevation compared to conventional 4 mg/0.1 ml injection.

Methods

A retrospective case study was performed in 48 patients (48 eyes) who received intravitreal triamcinolone acetonide injection and who had a minimum follow-up time of six months. Patients were randomly assigned to receive 4 mg/0.1 ml or 4 mg/0.05 ml (24 patients in each group).

Results

Before injection, mean IOP was 13.8±2.2 mmHg and 13.9±2.4 mmHg in the 0.1 ml and 0.05 ml group. The difference in IOP elevation between the two groups was statistically significant immediately after injection (P=0.000), one hour after injection (P=0.001), and one day after injection (P=0.000). After injection, the central macular thickness decreased significantly the of two groups. The difference of the central macular thickness decrease between both groups was not statistically significant.

Conclusions

An intravitreal triamcinolone acetonide 4 mg/0.05 ml injection will more quickly reduce the IOP elevation in the early phase compared to 4 mg/0.1 ml injection, while providing a similar effect on the change of central macular thickness.

Keywords: Central macular thickness, Intraocular pressure, Intravitreal triamcinolone acetonide injection

References

1. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979; 77:171–80.

2. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age‐ related macular degeneration. Retina. 2000; 20:244–50.

3. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136:791–6.

4. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999; 27:431–2.

5. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; 87:24–7.

6. Özkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005; 40:63–8.

7. Yang YH, Kim KR, Yang SW, Yim HB. The effect of intravitreal triamcinolone acetonide on intraocular pressure. J Korean Ophthalmol Soc. 2004; 45:1081–5.

8. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004; 138:740–3.

9. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003; 34:386–90.

10. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005; 19:122–7.

11. Jonas JB, Kreissig I, Degenring R. Secondary chronic open angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol. 2003; 121:729–30.

12. Gilles MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone:results from a randomized clinical trial. Arch Ophthalmol. 2004; 122:336–40.

13. Audren F, Lecleire‐ Collet A, Erginary A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.

14. Baath J, Ells AL, Crichton A, et al. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther. 2007; 23:304–10.

15. Heatley CJ, Lim KS, Siriwardena D, Barton K. Malignant glaucoma as a complication of intravitreal triamcinolone acetonide. Acta Ophthalmol Scand. 2006; 84:712–3.

Figure 1.

(A) Sedimentation of triamcinolone acetonide. (B) Only 0.05 ml from the inferior layer suspension.

Figure 2.

Evolution of intraocular pressure after intravitreal triamcinolone acetonide 0.05 ml or 0.1 ml injection.

Figure 3.

Serial change in mean central macular thickness in eyes of 0.1 ml and 0.05 ml triamcinolone acetonide injection.

Table 1.

Clinical characteristics of 48 patients receiving intravitreal injection of triamcinolone acetonide

Charateristics	Group A^*	Grou B^†	P-value
Number of eyes	24	24	
Age (years)	59.7±7.9	57.1±10.1	0.25^‡
Gender (male:female)	10:14	11:13	0.77^§
Lens (phakia:pseudophakia)	17:7	18:6	0.75^§
Underlying disease			0.86^§
Diabetic retinopathy	17	17	
CRVO^∏	5	4	
BRVO^#	2	3	

^* Group A = eyes injected with 0.1 ml (4 mg) of triamcinolone acetonide

^† Grou B= eyes injected with 0.05 ml of sedimented triamcinolone aceonide

^‡ Mann-Whitney U test

^§ Chi-square test

^∏ CRVO = central retinal vein occlusion

^# BRVO = branch retinal vein occlusion.

Table 2.

Mean (±SD^*) intraocular pressure in eyes of 0.1 ml and 0.05 ml triamcinolone acetonide injection

IOP^†(mmHg)	Eyes injected with 0.1 ml (n=24)	Eyes injected with 0.05 ml (n=24)	P-value^‡ of IOP difference between groups
Before injection	13.8±2.2	13.9±2.4	0.721
Immediately after injection	45.8±4.8	35.7±5.2	0.000
1 hour	35.5±3.2	29.2±3.4	0.001
1 day	20.7±2.2	17.6±3.0	0.000
1 week	14.7±1.4	14.2±2.7	0.195
2 weeks	15.2±0.9	14.8±2.3	0.226
4 weeks	15.5±1.3	15.6±2.2	0.983
8 weeks	16.1±1.3	16.5±2.5	0.237
12 weeks	18.9±1.3	18.5±1.8	0.736
6 months	15.4±1.6	15.9±2.0	0.346

^* SD = standard deviation

^† IOP= intraocular pressure

^‡ Mann-Whitney U test.

Table 3.

Mean (±SD^*) central macular thickness in eyes of 0.1 ml and 0.05 ml triamcinolone acetonide injection

CMT^†(µm)	Eyes injected with 0.1 ml (n=24)	Eyes injected with 0.05 ml (n=24)	P-value^‡ of CMT difference between groups
Before injection	548.0±76.9	510.8±84.3	0.205
4 weeks	228.3±29.0	243.8±37.7	0.093
12 weeks	234.1±30.6	225.8±36.1	0.293
6 months	459.1±49.9	432.3±62.6	0.069

SD^* = standard deviation

CMT^†=central macular thickness

^‡ Mann-Whitney U test.

TOOLS

Similar articles